News
Pressroom »

News

2013-10-25
Camurus awarded Best Innovation in Formulation at the CPhI Worldwide 2013
Camurus’ FluidCrystal® technology was awarded Best Innovation in Formulation at the CPhI Worldwide 2013, the world's leading pharmaceutical networking event, hosting over 30,000 attendees from 140 countries and 2,200 exhibitors. The CPhI Pharma Awards finalists showcased products and services ranging from nanonization of APIs to novel sterization solutions. The announcement of nine finalists in three classes was done one week prior to the conference in Frankfurt 22-24 October at Messe Frankfurt, allowing attendees to learn of the latest innovations seen across the pharmaceutical industry. After individual presentations by award finalists at the Speaker's Corners, Camurus’ was announced as winner of the Award for Best Innovation in Formulation for it’s long-acting FluidCrystal® Injection depot technology.

Winner in the other categories were API Corporation for Best Innovation in Process Development and E-Pharma for Best Innovation in Packaging.


2013-09-10
Camurus receives option-exercise milestone for octreotide FluidCrystal® product CAM2029
Lund, Sweden, September 10, 2013 – Camurus announced today that Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus’ FluidCrystal® Injection depot technology.

The option exercise is the next stage in the collaboration, option and license agreement between Novartis and Camurus executed in December 2011. It triggers an undisclosed milestone payment to Camurus from eligible potential payments of up to US$ 700 million, subject to achievement of predefined development, regulatory and commercial milestones for the products included in the agreement. In addition, Camurus is entitled to royalties on global product sales.

CAM2029 is a novel, long-acting octreotide product that has been developed by Camurus with the goal of easy subcutaneous administration in the treatment of patients with acromegaly and NETs. CAM2029 has received orphan drug designation by EMA for the treatment of acromegaly and has been studied in three clinical Phase I trials, assessing pharmacokinetics, pharmacodynamics and safety after single and repeat dosing. Following the option exercise, Novartis will assume responsibility for further clinical development of CAM2029, including any Phase III studies, product registration and worldwide commercialization.

“We are very proud of the successful development of our collaboration and look forward to continue assisting Novartis in the clinical development and registration efforts for CAM2029,” says Fredrik Tiberg, President and CEO of Camurus. “Novartis’ decision to acquire full commercialization rights to CAM2029 and related products is a key milestone for Camurus that further validates our advanced delivery technologies and clinical product development capacity. Novartis’ continued investment in this program strengthens our strategic relationship and enables Camurus to expand its proprietary pipeline of new and innovative therapies for serious diseases.”

Since the transaction triggers relevant value thresholds, Novartis’ binding commitment to complete the exercise of the option is subject to the US’s Hart-Scott-Rodino Antitrust Improvements Act of 1976 (15 U.S.C. §18a) (HSR).

About CAM2029
CAM2029 is a novel, ready-to-use, long-acting octreotide product for treatment of acromegaly and neuroendocrine tumors (NETs) based on Camurus’ proprietary FluidCrystal® delivery system. Octreotide chloride, the active ingredient of CAM2029 is a synthetic, cyclic octapeptide, an eight amino acid analogue of the peptide hormone somatostatin. The CAM2029 product is designed for easy and patient-friendly drug administration. While traditional depot therapeutics frequently comprise complex microsphere technology for intramuscular injection, Camurus' FluidCrystal® depot allows for subcutaneous injection of a small volume liquid that transforms into a biodegradable liquid crystal gel at the site of injection. Thereby the drug compound is effectively encapsulated, providing rapid onset and long-acting octreotide release.

About Camurus
Camurus is a research-based pharmaceutical company dedicated to developing innovative therapeutics for diseases with high unmet medical needs. The company’s current pipeline includes products for treatment of pain, opiate addiction, cancer and for use in endocrinology. Based on its advanced nanoscale drug-delivery technology platform, FluidCrystal®, Camurus is also active in a number of development partnerships and research collaborations with international pharmaceutical and biotech companies.

For further information, please contact:
Fredrik Tiberg, President & CEO
Tel: +46 (0)46 286 4692
fredrik.tiberg@camurus.com
www.camurus.com

2013-09-10
Camurus samarbetspartner köper licensrättighet till långtidsverkande peptidläkemedel
Lund, 10 september, 2013 – Läkemedelsföretaget Camurus meddelar idag att deras samarbetspartner, läkemedelskoncernen Novartis, utövat sin option att förvärva en exklusiv global licens för utveckling och kommersialisering av CAM2029, ett långtidsverkande läkemedel för behandling av patienter med akromegali och neuroendokrina tumörer.

Novartis beslut att utnyttja optionen till licensrättigheterna markerar ett avgörande steg i det pågående samarbetet mellan de båda företagen. Ett samarbete som inleddes december 2011 då företagen tecknade ett options- och licensavtal för CAM2029 och FluidCrystal® teknologin.

Novartis förvärv av licensrättigheterna ger Camurus en första milstolpsersättning av de upp till 700 miljoner dollar som företaget har rätt till, förutsatt att specifika utvecklings-, regulatoriska och kommersiella mål uppfylls. Utöver detta har Camurus rätt till royalty på Novartis globala försäljning av de läkemedelsprodukter som ingår i avtalet.

”Vi är fantastiskt nöjda med hur samarbetet med Novartis utvecklats och ser fram emot att fortsätta stödja dem under vidareutvecklingen och registreringen av CAM2029 på den globala marknaden.” säger Camurus verkställande direktör och forskningschef Fredrik Tiberg. ”Novartis beslut att förvärva licensen till CAM2029 är en tydlig bekräftelse på vår förmåga att utveckla innovativa teknologier och läkemedelsprodukter. Affären är dessutom ett stort finansiellt genombrott för oss och innebär bland annat att vi kan satsa ytterligare resurser på utveckling av vår egen forskningsportfölj.”

Då transaktionen överskrider vissa tröskelvärden är Novartis bindande ansvar att slutföra den föremål för amerikansk konkurrenslagstiftning enligt Hart-Scott-Rodino Antitrust Improvements Act of 1976 (15 U.S.C. §18a) (HSR).


Bakgrund

CAM2029
CAM2029 är ett långtidsverkande peptidläkemedel baserat på den aktiva substansen oktreotid och Camurus patenterade formuleringsteknologi, FluidCrystal®. Produkten är under utveckling för behandling av patienter med akromegali och neuroendokrina tumörer och har fått status som särläkemedel, s.k. orphan drug, av Europeiska läkemedelsmyndigheten (EMA).
CAM2029 är utvecklad för att enkelt kunna ges en gång i månaden av sjukvårdspersonal, eller patienten själv, via en injektion under huden. Därefter frisätts den aktiva substansen oktreotid i jämn takt och normaliserar överproduktion av hormoner som ligger bakom de allvarliga sjukdomstillstånd och symptom som patienter med akromegali och neuroendokrina tumörer uppvisar. CAM2029 har hittills genomgått tre kliniska fas 1-prövningar, som bland annat utvärderat dess farmakokinetik, farmakodynamik och säkerhet, med positiva resultat.

Camurus
Camurus är ett forskningsbaserat läkemedelsbolag som utvecklar innovativa läkemedel för sjukdomar där det finns tydliga medicinska behov och potential till avsevärt förbättrad behandling. Camurus forskningsportfölj innehåller produktkandidater för behandling av cancer och cancerbiverkningar, akromegali, smärta och drogberoende. Företaget har i egen regi och med partners tagit flera produkter till marknaden, senast episil® som behandlar symptom av oral mukosit, en vanlig och svår biverkan av kemoterapi och strålbehandling. Utöver egna projekt driver Camurus också ett flertal forsknings- och utvecklingssamarbeten med internationella biotech- och läkemedelsbolag, baserade på bolagets unika formuleringsteknologi, FluidCrystal®.

För ytterligare information, kontakta:
Fredrik Tiberg, vd och forskningschef
Tel: 046 286 46 92
fredrik.tiberg@camurus.com
www.camurus.com

2012-07-09
Cangene granted U.S. commercialization rights for episil® from Camurus
Lund, Sweden, July 6, 2012 – Camurus AB and Cangene Corporation announced today that they have entered into an agreement under which Cangene bioPharma Inc., a wholly-owned subsidiary of Cangene, will have exclusive rights to commercialize episil® in the United States for the management and relief of pain associated with oral lesions, including oral mucositis (OM), which results from cancer therapy and other causes. Cangene bioPharma plans to launch episil® in the United States in October 2012.
A severe side‐effect of cancer chemotherapy and radiotherapy, OM is characterized by painful ulceration and opportunistic mouth infections, and affects approximately 500,000 patients in the United States per year. OM is caused by damage to the DNA in the basal epithelial cell lining of the mouth leading to decreased cell proliferation ability. OM can limit the dosing and frequency of treatment for cancer, prevent patients from eating, and often necessitates hospitalization for re‐hydration, opiate pain medication and total parenteral nutrition. episil® has been clinically demonstrated to reduce pain for up to 8 hours. It is the first product for OM that is supplied as a ready-to-use, pocket-sized device, helping patients maintain their quality of life while undergoing cancer therapy.

“Lesions caused by OM are a painful reality for many patients undergoing cancer treatment and our research indicates a strong market need for alternative treatment options that will improve patients’ quality of life,” said John A. Sedor, President and CEO of Cangene. “In bringing episil® to the U.S, we are addressing a significant unmet medical need in a growing patient population, leveraging Cangene’s wealth of experience in hospitals and oncology clinics and advancing our strategic focus on late-stage, in-licensing opportunities.”

Fredrik Tiberg, President and CEO of Camurus said, “Cangene is an ideal partner for Camurus and episil®, with a highly experienced and effective sales and distribution structure targeting key haematology and oncology clinics in the U.S. We look forward to working closely together to provide a new and promising treatment alternative to patients across the U.S. who are suffering from OM and related problems”.

Financial terms of the agreement were not disclosed.

About episil®
episil® represents a new concept for local treatment of pain associated with OM. The product is administered as a lipid‐based liquid that spreads on the intra‐oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal film that mechanically protects the sensitized and sore epithelium of the oral cavity. episil® is conveniently administered from a ready to use multi‐dose device equipped with a metered pump. episil® has been clinically demonstrated to reduce pain for up to eight hours following administration. episil® is cleared as a medical device in the United States.

About Cangene
Cangene Corporation (TSX: CNJ), headquartered in Winnipeg, Canada, is one of the nation’s oldest and largest biopharmaceutical companies. It is focused on the development and commercialization of hospital and oncology clinic based therapeutics. Cangene’s products are sold worldwide and include products that have been accepted into the U.S. Strategic National Stockpile. Cangene has employees in six locations across North America. It operates manufacturing facilities in Winnipeg, Manitoba and Baltimore, Maryland (through its wholly-owned subsidiary, Cangene bioPharma, Inc.) where it produces its own products and undertakes contract manufacturing for a number of customers. Cangene operates three U.S. and one Canadian plasma-collection facilities operating under the name Cangene Plasma Resources. For more information about Cangene, visit the Company’s website at www.cangene.com.

About Camurus
Camurus is a research-based pharmaceutical company dedicated to developing innovative therapeutics for diseases with high unmet medical needs. The company’s current pipeline includes products for treatment of pain, opiate addiction, cancer and endocrinology. Camurus is also active in a number of development partnerships and research collaborations with international pharmaceutical and biotech companies. For more information about Camurus, visit the Camurus’ website at www.camurus.com.

For further information, contact:
Fredrik Tiberg
President and CEO, Head of R&D
Tel: +46 (0)46 286 4692
fredrik.tiberg@camurus.com

2011-12-13
Camurus tecknar exklusivt options- och licensavtal för det långtidsverkande peptidläkemedlet CAM2029, samt FluidCrystal® depåteknologi
Lund, 13 december, 2011 – Lundabaserade läkemedelsföretaget Camurus tillkännager idag att man ingått ett samarbets-, options- och licensavtal med det schweiziska läkemedelsföretaget Novartis. Avtalet avser utveckling, tillverkning och kommersialisering av Camurus läkemedelskandidat CAM2029, samt ytterligare produkter baserade på företagets depåteknologi FluidCrystal®.

Enligt avtalet erhåller Camurus en initial kontantersättning på 10 miljoner dollar. Utnyttjar Novartis optionsrätten, kan Camurus totala milstolpsersättningar komma att uppgå till mer än 700 miljoner dollar. Utöver detta har Camurus rätt till löpande royalties på global försäljning.

CAM2029 är ett långtidsverkande peptidläkemedel för behandling av akromegali och neuroendokrina tumörer (NET). Produkten har fått status som särläkemedel (s.k. “orphan drug”) av Europeiska läkemedelsmyndigheten (EMA). CAM2029 har hittills genomgått två kliniska prövningar med positiva resultat. Ytterligare en klinisk studie, som utvärderar farmakokinetik, farmakodynamik och säkerhet har nyligen startats och kommer att slutföras under tredje kvartalet 2012.

”Vi är givetvis mycket nöjda med affären. Novartis är ett av världens absolut främsta läkemedelsbolag. Deras forskning och utveckling inom endokrinologi och onkologi är världsledande och de har ett mycket starkt globalt försäljningsnätverk. Samarbetet innebär ett viktigt genombrott för Camurus. Nu har vi en stark partner till ett av våra viktigaste läkemedelsprogram och därmed utökad kapacitet att ta våra produkter och vår teknologi till marknaden” säger Camurus vd och forskningschef Fredrik Tiberg.

Bakgrund

Om FluidCrystal® injektionsdepå
Camurus FluidCrystal® injektionsdepå möjliggör kontrollerad frisättning av läkemedelsubstanser. Det innebär att dosering kan styras från daglig dosering, till en gång i veckan, eller så sällan som en gång i månaden. FluidCrystal® teknologin utnyttjar en patenterad lipidbaserad lösning som är enkel att tillverka, hantera och injicera, till skillnad från traditionella depåteknologier som t ex polymera mikropartiklar. Först efter injektion omvandlas vätskan till en flytande kristallin matris som snabbt och effektivt kapslar in aktiv substans. I takt med att depån successivt bryts ner frigörs läkedelssubstansen. Produkter baserade på FluidCrystal® är klara för användning och behöver inte blandas och rekonstitueras före användning. Sammantaget erbjuder teknologin ett unikt, patientvänligt och kostnadseffektivt alternativ för administration av aktiva substanser med begränsat peroralt upptag, eller kort halveringstid, som t ex peptid- och proteinläkemedel.

Om CAM2029
CAM2029 är ett peptidläkemedel för behandling av bland annat akromegali och neuroendokrina tumörer. Produkten är utvecklat för att ges en gång i månaden och kan tas av patienten själv. Läkemedlet injiceras enkelt under huden, varpå den aktiva substansen oktreotid frisätts i jämn takt och normaliserar överproduktionen av tillväxt- och gastrointestinala hormon. Överproduktionen av dessa hormoner är huvudorsaken till de allvarliga sjukdomstillstånd och symptom som patienter med akromegali och neuroendokrina tumörer uppvisar.

Om Camurus
Camurus utvecklar innovativa läkemedel för sjukdomar där det finns tydliga medicinska behov och potential till avsevärt förbättrad behandling. Camurus forskningsportfölj innehåller produktkandidater för behandling av cancer och cancerbiverkningar, endokrinologi, smärta och drogberoende. Företaget har i egen regi och med partners tagit flera produkter till marknaden, senast episil® som behandlar symptom av oral mukosit, en vanlig och svår biverkan av kemoterapi och strålbehandling. Utöver egna projekt driver Camurus ett flertal forsknings- och utvecklingssamarbeten med internationella biotech- och läkemedelsbolag.

För ytterligare information, kontakta:
Fredrik Tiberg, vd och forskningschef
Tel: 046 286 46 92
fredrik.tiberg@camurus.com
www.camurus.com

2011-12-13
Camurus enters exclusive collaboration, option and license agreement to its long acting octreotide product CAM2029 and the FluidCrystal® Injection depot technology
Lund, Sweden, December 13, 2011 – Camurus announces today that it has granted Novartis an exclusive option to license the FluidCrystal® Injection depot technology to develop, manufacture and commercialize Camurus’ octreotide product CAM2029 and related unnamed products.

CAM2029 is a ready-to-use, long acting octreotide product being developed for treatment of patients with acromegaly, neuroendocrine tumors (NETs), and other indications. CAM2029 has received orphan drug designation by EMA for treatment of acromegaly and has been studied in two completed clinical Phase I trials assessing single and repeat dosing. A further clinical trial investigating pharmacokinetics, pharmacodynamics, and safety of CAM2029 versus an active control was recently approved and initiated. This trial is expected to be completed and reported by the third quarter of 2012. ´

According to the agreement, Novartis will pay Camurus a non-refundable option fee of USD 10 million. Camurus will fund, perform and retain control over the clinical development of CAM2029 until exercise of the license option. If exercised, Novartis will thereafter assume responsibility for further clinical development, including pivotal studies, product registration and worldwide commercialization. Camurus is in total eligible to payments in excess of USD 700 million, subject to achievement of predefined development, regulatory and commercial milestones for the various products of the agreement. In addition, Camurus is entitled to running royalties on global product sales.

Fredrik Tiberg, President and CEO of Camurus, commented on the deal, "We are very pleased to have reached this agreement with Novartis, our partner of choice for CAM2029 and related assets, given their world class research, unique development capacity across relevant indications, as well as global market presence and leadership in endocrinology and oncology. We now look forward to working closely with the exceptional teams of Novartis to further accelerate and expand our product pipeline with the aim of introducing new treatment options to patients suffering from serious and life-threatening diseases.”

About FluidCrystal® Injection depot
The FluidCrystal® Injection depot delivers therapeutic levels of drug substance over extended periods – tunable from days to months – from a single injection. While traditional depot therapeutics comprise complicated microsphere technology, Camurus' depot offers a liquid solution that transforms into a controlled release liquid crystal gel matrix in situ on contact with minute quantities of aqueous fluid at site of injection. The FluidCrystal® delivery system overcomes traditional side effects associated with high initial drug release on injection (drug burst) and poor drug stability by effectively encapsulating the drug compound in the nanopores of the depot matrix throughout the entire process from injection until final degradation. This, together with the ready-to-use product design, makes the system highly suitable for sustained parenteral delivery of peptides and proteins.

About CAM2029
CAM2029 is a novel, ready-to-use, long acting octreotide product for treatment of acromegaly and carcinoid tumors. The product consists of a lipid-based liquid administered subcutaneously as a low volume injection. Once injected the lipid constituents immediately start to self-assemble into the "active" FluidCrystal® controlled release matrix. Therapeutic plasma levels of octreotide are thereby rapidly reached and maintained over several weeks, which suppresses the overproduction of growth hormone and gastrointestinal hormones and provides effective treatment for patients with acromegaly and NETs.

About Camurus
Camurus is a research-based pharmaceutical company dedicated to developing innovative therapeutics for diseases with high unmet medical needs. The company’s current pipeline includes products for treatment of pain, opiate addiction, cancer and endocrinology. Camurus is also active in a number of development partnerships and research collaborations with international pharmaceutical and biotech companies.

For further information, please contact:
Fredrik Tiberg, President & CEO
Tel: +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
www.camurus.com

2011-11-17
Camurus receives ISO 13485 certification
Lund, November 17th, 2011 – Camurus, a research based Swedish pharmaceutical development company, reports today that its Quality Management System has been certified to the requirements of both ISO 13485 and the Canadian Medical Device Conformity Assessment System (CMDCAS) by Intertek, a global leader amongst certification bodies.
ISO 13485 is the internationally recognized quality standard for development, manufacture and marketing of medical devices. With a quality system compliant to both ISO 13485 and CMDCAS, Camurus has further strengthened its' position with regards to the global marketing strategy for episil®, for treatment of oral mucositis, as well as for future medical device products in the pipeline.

About Camurus
Camurus is a research based pharmaceutical company based in Sweden and dedicated to developing innovative therapeutics for diseases with high unmet medical needs. The company’s current pipeline includes products for treatment of pain, opiate addiction, cancer and endocrinology. The company is also active in a number of development partnerships and research collaborations with international pharmaceutical and biotech companies.
For further information, please contact:

Fredrik Tiberg, President & CEO
Tel: +46 66 286 46 92
fredrik.tiberg@camurus.com

2011-10-31
Camurus completes phase I/II trial of CAM2038, buprenorphine FluidCrystal® depot, for treatment of opioid dependence
Lund, Sweden, October 31, 2011 – Camurus today announces positive results from a recently completed Phase 1/2 trial of its subcutaneous FluidCrystal® opioid dependence drug CAM2038. The trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug CAM2038 in patients dependent on opioids. Patients were assigned to one of the four CAM2038 treatment dose groups, allocated in accordance with pre-determined dose ranges of their pre-study treatment with sublingual buprenorphine (Subutex®or Suboxone®).

CAM2038 was found to be well tolerated both systemically and locally at all doses tested in the trial and no safety concerns were identified in the safety population (n=41). The pharmacokinetics obtained for CAM2038 demonstrate dose proportional and dose linear extended release of buprenorphine over at least 7 days with a rapid onset followed by slowly declining therapeutic serum levels of buprenorphine. The pharmacodynamics assessment of subjective and clinical opiate withdrawal symptoms (SOWS and COWS) were well controlled for up to 10 days after single-dose injection of CAM2038. Notably, these extended effects were seen for a dose that corresponded to only between one and two daily doses of sublingual Subutex® or Suboxone®. This suggests a very significant dose sparing, improvement in bioavailability and ultimately less buprenorphine on the street and less risk of drug diversion. The observation that the dose ranges of pre-study sublingual buprenorphine (Subutex® and Suboxone® ) and CAM2038 were compatible in terms of treatment effect (SOWS, COWS and time to rescue) between treatment groups indicates a relatively straightforward transition of patients from current treatment with once-daily sublingual buprenorphine to treatment with once-weekly CAM2038.

“CAM2038 combines a proven effective medication for patients with opioid dependence, buprenorphine, with an administration form and effect duration that is well suited to the current treatment practice for this group of patients, considering timing of matching psychiatric interventions and compliance aspects”, says Prof. Dr. Christian Haasen, Principal Investigator for the trial and Professor of Psychiatry at the University of Hamburg. “In light of the results from the present study, I believe CAM2038 is a promising therapeutic candidate for the treatment of opiate dependence.”
Opioid dependence is a chronic, often relapsing, disorder that contributes to major health and social challenges. It is a growing problem world-wide with currently about 5 million individuals in Europe and the U.S. using illicit opioids, such as heroin, according to the World Health Organization. A further 2.0 million individuals are estimated to be addicted to prescription opioid medications in the U.S. alone. However, only about 20 percent of the total opioid dependent population is currently receiving pharmacological treatment.
Following discussions with regulatory agencies in Europe and the US, Camurus intends to continue the clinical development of CAM2038 and plans to start a pivotal clinical trial for product registration in 2012.

About CAM2038
CAM2038 is a ready-to-use, buprenorphine FluidCrystal® injection depot developed for the treatment of opioid dependency by controlling or eliminating opiate craving and withdrawal symptoms, such as vomiting, sweating, stomach cramps, diarrhea, and muscle pain that increase the risk of relapse into misuse. In contrast to current treatments, including once-daily sublingual buprenorphine (Suboxone® and Subutex®) and methadone, CAM2038 is designed for less frequent (i.e. once-weekly) dosing. Delivery is in the form of a convenient, ready-to-use, small volume subcutaneous injection providing steady therapeutic plasma levels over time, at a significantly lower (5-10 times reduced) average daily maintenance dose in comparison to Subutex® and Suboxone®. The Camurus CAM2038 product also addresses the poor bioavailability, absence of dose proportionality, and variable plasma concentrations of sublingual buprenorphine, in addition to allowing much lower total treatment doses. Furthermore, the CAM2038 product is primarily intended as an office-based treatment, thereby reducing the issues of poor treatment compliance, misdirection and misuse, which are common for sublingual buprenorphine.

About Camurus
Camurus is a research-based pharmaceutical company developing innovative therapeutics for diseases with high unmet medical needs. The company’s current pipeline includes products for treatment of pain, opiate addiction, cancer and growth hormone disorders. Based on its technology leadership in drug-delivery, the company is also active in a number of development partnerships and research collaborations with pharmaceutical and biotech companies globally.

For further information, please contact:
Fredrik Tiberg, President & CEO
Tel: +46 66 286 46 92
fredrik.tiberg@camurus.com

2011-09-15
Camurus receives 510(k) clearance by the FDA to market episil® for oral pain management

Lund, Sweden, September 15, 2011 – Camurus announces today that it has received 510(k) clearance from the Food and Drug Administration (FDA) to market episil® in the United States for management and relief of oral pain. episil® is a patented lipid-based liquid that spontaneously forms an adhesive and protective barrier in contact with oral mucosa, thereby soothing oral lesions of various etiologies, including oral mucositis, a common side-effect of cancer treatments with radiotherapy or chemotherapy. Oral mucositis is an inflammation and ulceration of the oral mucosa that can cause severe pain and be highly debilitating for the patient. In many cases, hospitalization is required for pain management and parenteral nutrition.

 

episil® has in clinical studies been demonstrated to safely and effectively reduce oral pain for this patient group, for whom earlier treatment options were limited primarily to strong opioid analgesics and local anesthetics. It is supplied in the form of a small convenient spray device containing 10 ml lipid solution providing between one and two weeks of treatment.

 

The episil® product is currently being launched and marketed across EU and Israel by Camurus’ regional commercial partners. “Through the 510(K) clearance we are now able to make episil® available to patients in the United States, with further countries to follow in the near future. This is an important step towards building a global distribution network for episil®” said Fredrik Tiberg, President and CEO of Camurus.

 

Camurus is a research-based pharmaceutical company developing innovative therapeutics for diseases with high unmet medical needs. The company’s current pipeline includes products for treatment of pain, opiate addiction, cancer and growth hormone disorders. Based on its technology leadership in drug-delivery, the company is also active in a number of development partnerships and research collaborations with pharmaceutical and biotech companies globally.

 


Contact:


Liselotte Larsson,

Senior Director, Business Development & Alliances

Tel: +46 (0)46 286 57 38


or


Fredrik Tiberg

President and CEO, Head of R&D

Tel: +46 (0)46 286 4692

 


2011-08-31
Teva new distributor of episil® in five European countries

Lund, Sweden, August 31, 2011 - Camurus’ partner for episil® in EU , Sinclair IS Pharma plc (AIM:SPH.L) (“Sinclair IS”) has today announced that it has signed a license agreement with Teva Pharmaceutical Industries Ltd (“Teva”) for the cancer supportive care product, episil®. Under the terms of the agreement, Teva will have the exclusive commercialisation rights for episil® in Germany, Spain, Poland, Switzerland and the Czech Republic, see Sinclair IS press release.

 

"This new partnership with Teva is very positive for episil®, and patients suffering from oral mucositis. Teva is a highly competent and strong commercialization partner in these territories with an excellent reach into the oncology supportive care segment", comments Fredrik Tiberg, President and CEO of Camurus.

 

For more information about episil®, please visit www.episil.net or contact:

 

Liselotte Larsson

Senior Director, Business Development & Alliances

Tel: +46 (0)46-286 57 38

 

Fredrik Tiberg

President and CEO, Head of R&D

Tel: +46 (0)46 286 4692


2010-09-30
New pain treatment for patients suffering from oral mucositis

Lund, Sweden. September 30, 2010 – The research-based pharmaceutical company Camurus introduces episil® for treatment of pain associated with oral mucositis, a common side-effect of chemo- and radiotherapy.

Oral mucositis is an inflammation and ulceration of the oral mucosa. It may cause severe pain and be highly debilitating for the patient. In severe cases hospitalization is required for pain management and nutrition.

episil® offers a new treatment option for a group of patients, which earlier options have primarily been opioids and local anesthetics for pain relief. episil® consists of a patented combination of lipids that spontaneously forms an adhesive and protective barrier in contact with the oral mucosa. This has been demonstrated to provide effective pain relief for up to eight hours, without reported side-effects. episil® is administered using a convenient pocket sized spray device. The container contains 10 ml lipid solution corresponding to between one and two weeks of treatment.

episil® is from October 2010 marketed in the Nordic countries through Camurus. IS Pharma Ltd has acquired license and distribution rights for the rest of EU and have launched the product in the UK.  episil® is expected to reach the rest of the EU markets during the coming year.
 
Camurus is a research-based pharmaceutical company developing innovative therapeutics for diseases with high unmet medical needs. The company’s current pipeline includes products for treatment of pain, opiate addiction, cancer and growth hormone disorders. Based on its technology leadership in drug-delivery, the company is also active in a number of development partnerships and research collaborations with pharmaceutical and biotech companies globally. See also www.camurus.com.  

For more information about episil®, please visit www.episil.net or contact:

Liselotte Larsson
Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38
Or
Fredrik Tiberg
President and CEO, Head of R&D
Tel: +46 (0)46 286 4692


2010-03-04
IS Pharma acquires exclusive European rights for Episil® from Camurus

Lund, Sweden. March 4, 2010 - Camurus AB and IS Pharma plc (LSE:ISPH) announce today that they have entered into a license and distribution agreement for Episil®, an oncology supportive care product developed by Camurus. Camurus receives a consideration of €1.75 million and royalties for the exclusive rights in the European territories.

Episil® is a patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment.  Episil® creates a strongly bioadhesive FluidCrystal® film that protects sensitive and sore areas of the mouth. Episil® provides pain reduction during at least eight hours and is presented in a patient friendly multi-dose device. 

IS Pharma plans to launch Episil® across Europe through 2010 and 2011. The market for such products in Europe is estimated at £200 million. IS Pharma has distribution rights for all European territories (EU and Switzerland) with the exception of Sweden, Denmark, Finland, Norway and Iceland where Camurus will commercialise the product directly in close partnership with IS Pharma.

Tim Wright, CEO of IS Pharma said: “We are delighted to become Camurus’ exclusive partner in Europe for Episil®. This partnership represents further success in the delivery of our strategy of building IS Pharma through the acquisition and growth of specialist hospital medicines; with a particular focus on higher margin patented products.

Fredrik Tiberg, CEO of Camurus said: “We are very pleased to have signed this agreement with IS Pharma who have clearly demonstrated their ability to grow products in the specialist hospital medicines market across Europe.  Camurus sees a strong synergy for Episil® with IS Pharma’s product portfolio and looks forward to the success of the product in Europe.”

Oral mucositis is a severe side-effect of cancer chemotherapy or radiotherapy.  It is caused by damage to the DNA in the basal epithelial cell lining of the mouth leading to decreased cell proliferation ability which may result in ulceration and opportunistic mouth infections.  Oral mucositis is often a dose-limiting factor in the treatment of cancer.  In more severe cases, oral mucositis can be extremely painful, preventing the patient from eating and necessitating hospitalization for re-hydration, opiate pain medication and total parenteral nutrition.  It is estimated that in the UK, Germany, France Italy and Spain there are approximately 1.25 million cancer patients receiving chemotherapy or radiotherapy that could lead to oral mucositis.

Episil® represents a new concept for local treatment of pain associated with oral mucositis.  The product is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal® film that mechanically protects the sensitised and sore epithelium of the oral cavity. Episil® is conveniently administered from a ready to use multi-dose device. Episil® has been demonstrated to give an immediate and significant reduction of pain caused by oral mucositis.  This analgesic effect was maintained over at least eight hours following administration. Episil® has been registered as a medical device across Europe and has been granted the CE mark.  The product is protected by patent until 2025.

Camurus is a life science company providing innovative, nanoscale drug delivery systems for development of new and improved, high-value therapeutics.  Application of the company’s FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery.  These are used in developments programs with biotech and pharma companies worldwide.  Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and currently has four products in clinical development.
To find out more please go to www.camurus.com    

IS Pharma plc
(LSE: ISPH) is a fast growing, profitable business which develops, acquires and commercialises late stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Based in the UK, IS Pharma commercialises its portfolio in the UK directly and internationally through a strong network of distributors.
To find out more please go to www.ispharma.co.uk  

For more information, contact:

Fredrik Tiberg
President & CEO
Tel: +46 (0)46-286 46 92

Liselotte Larsson
Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38


2010-01-26
Camurus has initiated a repeat dose clinical trial of CAM2029, its long-acting octreotide chloride product

Lund, Sweden. 26 January, 2010 – Camurus announces that following the approval of its clinical trial application by the German BfArM, dosing has today been initiated in a repeat dose clinical study to further document pharmacokinetics, pharmacodynamics, and safety of its long-acting octreotide chloride drug product (CAM2029). The product is being developed for treatment of acromegaly and carcinoid tumours. The clinical trial, carried out in Germany, involves seventy healthy subjects, and includes the active comparator drug Sandostatin® LAR® from Novartis. The study protocol has been reviewed in a protocol assistance procedure by EMEA; endorsing the study, including the primary as well as all secondary objectives, as part of the overall development program for registration of CAM2029.

Camurus’ CEO Fredrik Tiberg comments: “This is an important study to Camurus. It is our first repeat dose trial featuring CAM2029. The study is designed to demonstrate key features of CAM2029 and the FluidCrystal® Injection depot system (including pharmacokinetics, biomarker effects and local tolerability) and to facilitate comparison with current gold standard treatment. The trial is intended to laying the foundation for a pivotal clinical phase III trial of CAM2029 in acromegaly patients early 2011.”

Acromegaly is a serious and rare hormonal disorder. It is caused by prolonged overproduction of growth hormone by the pituitary gland, in more than 90% of cases originating from a benign pituitary tumor (pituitary adenoma). It is most frequently diagnosed in middle-aged adults and leads to an increased morbidity and mortality if left untreated.

CAM2029 is a new ready-to-use, long-acting octreotide product for treatment of acromegaly and carcinoid tumours (and other gastro-entero-pancreatic neuroendocrine, GEP NE, tumours). The product is based on Camurus’ proprietary FluidCrystal® Injection depot drug delivery system. This system consists of a lipid-based liquid with dissolved drug compound (e.g. octreotide chloride) that can be administered subcutaneously as a low volume injection. Once injected the lipid constituents immediately start to self-assemble into the "active" FluidCrystal® controlled release matrix. This allows a rapid establishment of therapeutic plasma levels which in the case of CAM2029 are maintained during one month following a single injection. Compared to current marketed products CAM2029 offers the advantage of being more convenient to handle and easy to administer.  The ready-to-use product design, thin needle, small injection volume and room temperature storage stability allows for easier handling and administration, not only by healthcare professionals but also by patients/partners in the home-setting. Based on the potential significant benefits for patients, including improved quality of life, CAM2029 was recently granted orphan drug designation by the EMEA (EU/3/09/645; granted 12/6/2009).

Camurus is a life science company providing innovative, nanoscale drug delivery systems for development of new and improved, high-value therapeutics. Application of the company’s FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in developments programs with biotech and pharma companies worldwide. Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and currently has four products in clinical development.

For more information, contact:

Fredrik Tiberg
President & CEO
Tel: +46 (0)46-286 46 92

Liselotte Larsson
Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38


2009-05-26
Camurus receives positive opinion for orphan drug designation for CAM2029

Lund, Sweden. 26 May, 2009 – Camurus announced today that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the application for orphan designation for Camurus’ drug product CAM2029 (octreotide chloride FluidCrystal® Injection depot) for treatment of acromegaly. Criteria for the designation as an orphan drug are the low prevalence of the disease (less than 5 in 10,000 inhabitants of the EU), severity of the disease, and the expected significant benefit for the patients.

"We are very pleased with the positive opinion by COMP for orphan designation of our long-acting octreotide product CAM2029. This is an important milestone in our product development, confirming the clinical benefit of our product, and facilitating the further clinical development and product registration, "says Fredrik Tiberg, President & CEO of Camurus.

Subject to a confirmatory Commission Decision, Camurus will gain access to a number of development incentives, including: facilitated access to the centralized procedure scientific advice during the product development phase of CAM2029, reductions and exemptions of fees for protocol assistance and applications for marketing approval, and 10 years marketing exclusivity throughout Europe.

CAM2029 is a new ready-to-use, long-acting octreotide drug product being developed for treatment of acromegaly and carcinoid tumours (and other gastro-entero-pancreatic neuroendocrine, GEP-NE, tumours). CAM2029 consists of a lipid-based liquid in a prefilled syringe with a thin needle and it is administered subcutaneously as a low volume injection. This allows for easy and convenient administration also by patients themselves. Once injected the lipid constituents immediately start to self-assemble into the FluidCrystal® controlled release matrix. Therapeutic plasma levels of octreotide are rapidly reached and maintained over one month. Results from the initial Phase I clinical trial indicated a high bioavailability and favorable suppression of the clinical biomarker insulin-like growth factor 1 (IGF-1). The safety profile was found to be excellent with a reported very good local tolerability at the injection site and systemic adverse events being limited to transient gastrointestinal side-effects related to octreotide itself. A follow-up Phase IIb trial is in progress.  "With the incentives afforded by the orphan drug designation, we look forward to working with EMEA in the development of CAM2029," said Fredrik Tiberg.

Acromegaly is a serious and fortunately rare hormonal disorder caused by excess production of growth hormone by the pituary gland, in more than 90% of cases from a benign pituitary tumor (pituitary adenoma). It is most frequently diagnosed in middle-aged adults and leads to an increased morbidity and mortality if left untreated.

Camurus is a life science company providing innovative, nanoscale drug-delivery systems for development of new and improved, high-value therapeutics. Applications of the company’s FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in developments programs with biotech and pharma companies worldwide. Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and currently has four products in clinical development.

For more information, please contact
Fredrik Tiberg
President & CEO
Tel: +46 (0)46-286 46 92

Liselotte Larsson
Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38


2009-05-12
Camurus receives CE mark for Episil®

Lund, Sweden, May 12, 2009 – Camurus has been granted CE mark certification for the oral mucositis product Episil® from the Swedish Medical Products Agency. Episil® has been developed by Camurus for management of pain associated with oral mucositis.

Episil® has been demonstrated in clinical trials to give an immediate and long-lasting reduction of pain in patients suffering from oral mucositis. The product acts by forming a physical barrier which protects the sore surfaces in the oral cavity for a documented period of at least 8 hours.

 Fredrik Tiberg, CEO of Camurus comments:”The successful registration of Episil® is a very important milestone achievement for Camurus in an area where the unmet medical need is high."

 Oral mucositis can be an extremely painful and debilitating condition in which patients undergoing radiation or chemotherapy develop severe mouth ulcerations. Oral mucositis is caused by damage to the DNA in the basal epithelial cell lining of the mouth leading to decreased cell proliferation ability which may result in ulceration and opportunistic mouth infections. Oral mucositis is often a dose-limiting factor in the treatment of cancer. In more severe cases, oral mucositis can prevent the patient from eating and necessitating hospitalization for re-hydration, opiate pain medication and total parenteral nutrition.

 Episil® represents a new concept for local treatment of pain associated with oral mucositis. The product is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal® film that mechanically protects the sensitized and sore epithelium of the oral cavity. Episil® is conveniently administered from a ready to use multi-dose device.

Camurus is a life science company providing innovative, nanoscale drug-delivery systems for development of new and improved, high-value therapeutics. Application of the company’s FluidCrystal® delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in developments programs with biotech and pharma companies worldwide. Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and currently has four products in clinical development.

For more information, please contact
Fredrik Tiberg
President & CEO
Tel: +46 (0)46-286 46 92

Liselotte Larsson
Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38


2009-02-24
Camurus initiates a Phase I/II Clinical Trial of CAM2038, a new treatment concept for opiate addiction

Lund, Sweden, February 24, 2009 – Camurus announced today that it has received approval by the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) to start a clinical Phase I/II trial of CAM2038, a new potential treatment for opiate addiction. The trial, which will be carried out in Germany, will investigate the tolerability, pharmacokinetics, and pharmacodynamics of CAM2038 in 24 patients with opiate addiction, with the first subject expected to be recruited in the study imminently.

Fredrik Tiberg, CEO of Camurus says: "We are very enthusiastic to start the clinical development of our prospective anti-addiction drug, CAM2038, which we hope will become a significant new option for treating patients suffering from addiction to opiates."

Opiate addiction is a growing worldwide problem, including addiction to heroin and opiate analgesics. Heroin dependence is further linked to transmission of viral diseases and high crime rates. Nearly 3 million individuals in the US and Europe are addicted to opiates. It has been scientifically documented that addiction to opioids can be effectively treated through a number of interventions, including maintenance therapy with methadone and buprenorphine.

CAM2038 represents a new treatment concept for opiate addiction based on the well-documented anti-addiction therapeutic buprenorphine. While the current buprenorphine products on the market rely on frequent administrations of sublingual buprenorphine tablets, CAM2038 is based on a once-weekly or once-monthly subcutaneous administration that can be given by health-care professional in a clinical setting. This allows for better treatment compliance and safeguards against misuse and drug diversion. CAM2038 also has the potential to give more consistent therapeutic buprenorphine levels with less variability between administrations and over time.  

Camurus is a life science company providing innovative, nanoscale drug-delivery systems for development of new and improved, high-value therapeutics. The company’s FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in developments programs with biotech and pharma companies worldwide. Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and currently has four products in clinical development.

For more information, please contact
Fredrik Tiberg
President & CEO
Tel: +46 (0)46-286 46 92

Liselotte Larsson
Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38


2008-12-02
Camurus announces postive Phase IIa results for treatment of prostate cancer

Lund, Sweden, December 2, 2008 - Camurus reports positive results from a Phase IIa clinical trial with Camurus’ drug product CAM2032 for the treatment of prostate cancer. The product will be the first true ready-to-use, long-acting leuprolide formulation on the market. It is designed for convenient administration, including self-administration by patients, without the complication of reconstitution and mixing before injection.

CAM2032 is a novel, extended release formulation of the established anti-prostate cancer drug leuprolide. Leuprolide is a luteinizing hormone-releasing hormone (LHRH) agonist used for suppression of testosterone in treatment of prostate cancer. The study results showed clinically significant suppression of testosterone during the treatment period. Moreover, treatment was safe and well tolerated.

“We are strongly encouraged by the outcome of this clinical trial, showing that CAM2032 is effective for at least one month even at the lowest administered dose” says Fredrik Tiberg, President & CEO of Camurus. “In addition to confirming our primary goal for CAM2032, the results provide validation of the excellent performance and safety of our FluidCrystal® Injection depot system.”

Camurus has now finalized the formulation development of the one-month product and plans continued clinical product development of CAM2032 towards registration.

Prostate cancer
is the most common form of cancer in men, and the second leading cause of cancer death. In the US 200 000 new cases of prostate cancer were estimated for 2007, with a mortality rate of 27,050. In 2005 127,490 new cases were diagnosed in the 5 biggest European countries.

CAM2032
consists of a lipid-based formulation of leuprolide, ready loaded into a standard pre-filled syringe that is also compatible with auto-injector devices. It is administered as a low volume subcutaneous injection that rapidly transforms in situ into the FluidCrystal® controlled release matrix, providing consistent therapeutic plasma levels over the treatment period.

The goals of the Phase IIa clinical trial were to assess the serum testosterone levels, to investigate the pharmacokinetics (PK), and to show the safety and tolerability after single dose injections of CAM2032 at three different dose levels. The study was a single-dose, open-label, first-in-man, multi-centre cohort trial of 27 patients with metastatic prostate cancer. The results of the Phase IIa clinical trial demonstrated that the median time of suppression of testosterone to serum levels below 50 ng/dL was at least 43 days when CAM2032 was administered subcutaneously. The duration of testosterone suppression was dose related. A dose proportional relationship was also indicated between the primary PD parameter, i.e. duration of suppression, and the PK parameters Cmax and AUC0-∞. The trial further showed that treatment with CAM2032 was safe and well tolerated with no local reaction at the injection site. The study featured both subcutaneous buttock injections (one dose, N=6) and subcutaneous abdominal injections (three doses, n=21), with similar pharmacokinetic and pharmacodynamic readouts.

Camurus is a life science company providing innovative, nanoscale drug-delivery systems for development of new and improved, high-value therapeutics. The company’s FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in developments programs with biotech and pharma companies worldwide. Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and currently has three products in clinical development.

For more information, please contact
Fredrik Tiberg
President & CEO
Tel: +46 (0)46-286 46 92


Liselotte Larsson

Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38


2008-09-04
Camurus announces option and license agreement with Wyeth Pharmaceuticals

Camurus announced today that it has entered into an option and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). The agreement is for the evaluation and development of hemophilia therapeutics with Camurus´ proprietary FluidCrystal® nanoparticle delivery technology. According to the terms of the agreement, Camurus will receive an upfront payment, development milestones and royalty payments.

“We are very pleased to enter into this collaboration with Wyeth, where our combined expertise and resources will be directed at improvements of essential product features and the quality-of-life of the target patient group” said Fredrik Tiberg, President & CEO of Camurus. Wyeth is a major pharmaceutical company with one of the strongest biotech product pipelines globally. Camurus has a strategic focus in this area with several ongoing development projects of protein and peptide therapeutics using its FluidCrystal® delivery technologies. “The Wyeth collaboration will focus on developing advanced hemophilia therapeutics and is another step towards our goal of establishing a set of strategic partnerships with leading biopharmaceutical companies.”

Camurus AB is a life science company providing innovative, nanoscale drug-delivery systems for development of new and improved, high-value therapeutics. The company’s FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in development programs with biotech and pharma companies worldwide. Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and has currently three products in clinical development.
 

For more information;
visit www.camurus.com
or contact:
Liselotte Larsson
Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38


2008-05-30
Camurus reports positive Clinical Phase II results for a new treatment concept of oral mucositis pain

In a recently completed clinical trial of CAM2028 for treatment of oral mucositis pain, the product was shown to give an immediate and significant reduction of oral pain maintained over eight hours following intra-oral administration.

CAM2028 represents a new treatment concept for intra-oral pain associated with oral mucositis. Oral mucositis can be an extremely painful and debilitating condition in which patients undergoing radiation or chemotherapy develop severe mouth ulcerations. CAM2028 consists of a lipid-based liquid that spreads on the intra-oral mucosal surfaces and spontaneously transforms into a protective and strongly bioadhesive lipid lining. This lining is clinically documented to be uniquely retained over extended periods of time, also at exposed areas such as the oral cavity. The product is based on Camurus’ proprietary FluidCrystal® drug delivery system which is used for topical and parenteral extended release medications.
“We are strongly encouraged by the outcome of this study” says Fredrik Tiberg, President & CEO of Camurus. “The results confirm our expectations on the FluidCrystal® system based on its unique film-forming and protective properties.”

The main objective of this Proof-of-Concept trial was to investigate the local analgesic effect of CAM2028, along with assessment of safety and tolerability. The study was a multi-centre, cross-over, double-blind, single-dose, randomised Phase II trial with thirty eight head-and-neck cancer patients suffering from symptomatic oral mucositis (grade 2 or above) in week 3 to 4 of radiotherapy with a pain score of at least 6 on a 0-10 Likert scale. The mean observed pain intensity difference (PID) before and after treatment was 40 percent which was sustained during eight hours. Furthermore, the onset of the effect was rapid; less than five minutes. Based on the study outcome, the company proceeds with the development program and plans to register a first medical device product to be on the market during fist half of 2009.

Camurus is a life science company providing innovative, nanoscale drug-delivery systems for development of new and improved, high-value therapeutics. The company’s FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in developments programs with biotech and pharma companies worldwide. Camurus also develops drug products targeting improved performance, safety, and patient compliance of existing drug compounds and has currently three products in clinical development.

For more information, please contact

Fredrik Tiberg
President & CEO
Tel: +46 (0)46-286 46 92

Liselotte Larsson
Senior Director, Business Development & Alliances
Tel: +46 (0)46-286 57 38
 
www.camurus.com


2008-03-18
DiObex and Camurus sign license agreement for the development of DIO-901 in FluidCrystal® extended release technology

Development program for prevention of insulin-induced hypoglycemia in diabetes
San Francisco, California and Lund, Sweden, March 18, 2008

DiObex and Camurus announced today that they have signed a license agreement to develop DIO-901 (very low dose glucagon) in the Camurus drug delivery technology, FluidCrystal®. The development candidate is an extended release formulation of low dose glucagon for the prevention of insulin-induced hypoglycemia in patients with diabetes.

“Intensive glycemic control is beneficial for patients with diabetes, but it increases their risk of hypoglycemia which can lead to a spectrum of problems ranging from reduced quality of life to coma and death,” said David Cory, DiObex CEO. “This license agreement and development program reflects our commitment to deliver an extended release form of low dose glucagon to the market for the prevention of insulin-induced hypoglycemia.”

There is no product approved for the prevention of insulin-induced hypoglycemia in patients with diabetes. DiObex has successfully completed 3 Phase 1 proof-of-principle studies using very low dose glucagon infusions in type 1 diabetic patients. DIO-901 has received Fast Track status from the FDA for this program. The DIO-901 FluidCrystal® extended release formulation is scheduled to enter human clinical trials in the second half of 2008.

"We are very pleased to enter into this license with DiObex and have great hope for the development of DIO-901. The extended release version of DIO-901 using our FluidCrystal® delivery technology has the prospect to fulfill an important medical need in the treatment of diabetes," said Fredrik Tiberg, President & CEO of Camurus AB.

Terms of the agreement include an undisclosed signing fee, development milestones, future royalties on product sales and share of any potential DiObex sublicensing revenues.

About DiObex
DiObex, Inc., is a privately held biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin- induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and in a convenient disposable subcutaneous delivery device. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease.
For more information, visit
www.diobex.com.

About Camurus AB
Camurus AB is a biotechnology company providing innovative, nanoscale drug-delivery systems for development of new and improved, high-value therapeutics. The company’s FluidCrystal® gel and nanoparticle delivery technologies range from long-acting in-situ forming depots for small molecules and peptides to lipid nanocarriers designed for intravenous, oral and transdermal delivery. These are used in developments programs with biotech and pharma companies worldwide. Camurus also develops its own drug products targeting improved performance, safety, and patient compliance of existing drug compounds and has currently three products in clinical development.
For more information visit:
www.camurus.com.

SOURCE DiObex, Inc.; Camurus AB

Contact:

Liselotte Larsson, PhD
Business Development & Alliances of Camurus AB
+46-46-286 57 38
liselotte.larsson@camurus.com

Keith Vendola, MD
Corporate Development of Diobex, Inc. 
+1-415-551-4115,
keith@diobex.com


2007-06-13
Camurus awarded the best private biotech in Medicon Valley

Camurus won the award out of six biotech companies from Denmark and Sweden, which were nominated for the Strictly Financing Award 2007. After business presentations a panel of six British investors elected Camurus "The Best Private Biotech Company in Medicon Valley in 2007".

- We are delighted and honoured with the award. This day has proved that Danish and Swedish biotech represents very solid and strong companies. The award is a recognition of our potential to stay successful and expand and with that we are pleased, said Fredrik Tiberg, President and CEO, Camurus.

In the panel of judges it was agreed that Danish-Swedish biotech puts on an impressive performance.

- The standard of the six nominees was very high and it was a close race. We went for Camurus, partly because they demonstrated a carefully prepared and cost-effective strategy, said Patrick Lee from the British investor Advent Venture Partners on behalf of the panel of judges.

For further information, read the MVA press release 12.06.2007 at www.mva.org.

Or go to www.strictlyfinancing.com


2007-05-23
Camurus receives research grant

Camurus has been granted 3 million SEK from VINNOVA’s (Swedish Governmental Agency for Innovation Systems) programme “Forska&Väx”. The funding will be used to launch a new R&D program on a long-acting drug product for treatment of opioid addiction.

VINNOVA received grant applications from 366 Swedish SME companies for a total of over 600 million SEK. Thirty nine of these companies were granted 50.5 million SEK in total.


2007-05-02
Camurus to start enrollment in prostate cancer trial

Camurus has received approval to initiate a Phase I/II clinical trial of CAM2032, the company's long-acting LHRH agonist therapy for prostate cancer. The clinical trial is a single-dose, dose-escalating, open-label, multi-centre, cohort trial performed to determine the leuprolide drug serum profile and the serum testosterone suppressing effects after a single subcutaneous administration of three different doses of CAM2032. 24 male patients with advanced/metastatic prostate cancer will complete the trial. Assessment of safety of the investigational product CAM2032 is a further key objective of this clinical trial.

Prostate cancer is among the most commonly diagnosed cancers. It is the second leading cause of cancer death in male Americans. In 2005, the incidence of new cases of prostate cancer in the US was 238,397 and this is estimated to increase to around 250,000 in 2010. The worldwide market for LHRH agonist treatment in 2006 exceeded 3 billion US$.

Leuprolide (leuprorelin acetate) is a synthetic nonapeptide analogue of luteinising hormone-releasing hormone (LHRH) and acts as an LHRH receptor agonist. LHRH agonists are a recommended treatment for locally advanced and metastatic prostate cancer (Prostate Cancer Guidelines: European Association of Urology 2005). The drug down-regulates serum concentration levels of testosterone to inhibit tumour growth. For continuous therapeutic suppression of androgen levels, a prolonged delivery of LHRH agonist is required and several sustained release strategies for leuprolide have been developed.

CAM2032 is a new depot formulation of the market leading LHRH agonist leuprolide (leuprorelin acetate) exploiting Camurus’ delivery system – FluidCrystal®. The combination of the well established safety and efficacy of leuprolide with the novel and patient friendly delivery provided by FluidCrystal®, results in a substantial advance in the appeal and applicability of this treatment for prostate cancer.

CAMURUS AB is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical and biotech companies worldwide, the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products and to revive stalled pipeline projects.

For further information, please contact:

Fredrik Tiberg, President & CEO, Head of R&D, +46 (0)46 286 3863, info@camurus.com


2007-04-24
Camurus announces positive phase 1 results with its new long-acting octreotide product CAM2029

CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. The product utilizes Camurus’ FluidCrystal® delivery system; providing patient friendly subcutaneous administration and an advantageous pharmacokinetic profile comprising rapid onset, stabilization and long-acting release of octreotide.

The clinical trial was a double-blind, randomized, parallel-group, placebo-controlled trial for the assessment of safety, pharmacokinetics and pharmacodynamics in 32 healthy volunteers. Single-dose injections of three subcutaneous doses and one intramuscular dose of CAM2029 and the corresponding placebo FluidCrystal® formulations were administered. The local tolerability at the injection sites was very good. Systemic safety was also good with the most common adverse events being transient gastrointestinal side-effects related to octreotide. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the target one-month therapeutic period.

”We are extremely happy with the outcome of this pivotal trial confirming the therapeutic potential of the new long-acting octreotide product, CAM2029, as well as the competitive performance and safety of the FluidCrystal® delivery system itself. The delivery system is currently exploited in a range of in-house and partner development programs of new and improved drug products” says Fredrik Tiberg, President and CEO of Camurus.

Acromegaly is a hormonal disorder that occurs when the pituitary gland produces excess gonadotropin primarily due to the presence of a benign tumour - a pituitary adenoma. The condition is often diagnosed late, leading to high morbidity and mortality rates, in particular, because of associated cardiovascular, cerebrovascular and respiratory disorders and malignancies. The prevalence of acromegaly is approximately 60 per million.

Carcinoid tumours are the most common neuroendocrine tumours of the gastrointestinal tract, with an estimated prevalence of 21 per million. The 5-year life expectancy for untreated disease is only 8–21%. Of patients with carcinoid tumour, 10% will develop carcinoid syndrome, often after metastatic spread to the liver has occurred.

VIP-producing tumours (VIP-omas) are rare endocrine tumours, around 90% originate in the pancreas, which produces an excess of VIP. This over production leads, in turn, to profound and chronic watery diarrhoea and resultant dehydration, hypokalaemia, achlorhydria vasodilation, hypercalcaemia and hyperglycaemia.

CAMURUS AB is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical and biotech companies worldwide, the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products and to revive stalled pipeline projects.

For further information, please contact:

Fredrik Tiberg, President & CEO, Head of R&D, +46 (0)46 286 3863, info@camurus.com


2007-04-18
Camurus presenting and exhibiting at BIO 2007 Annual International Convention

Camurus management will give a presentation at the BIO 2007 Annual International Convention in Boston (USA) on Wednesday, 9 May at 11:30 am in Room B, at the 2007 Business Forum. The company is exhibiting at Booth #2065 in the Scandinavian Pavilion.

Fredrik Tiberg, President & CEO, will provide an overview of Camurus, its product pipeline, and FluidCrystal® delivery technologies. The presentation will include an update on the company’s clinical development programmes for treatment of acromegaly and carcinoid tumours, prostate cancer, and oral mucositis.

For further information about Camurus, please visit www.camurus.com.


2007-02-16
Camurus to launch proof-of-concept trial of pain treatment of oral mucositis in cancer patients

Camurus has received approval to begin a Phase II proof-of-concept clinical trial of CAM2028 for the treatment of pain in oral mucositis. The multicenter trial will be conducted in the EU and enrolment of the first patient begins in March 2007.

CAM2028 is a mucoadhesive, extended-release formulation of benzydamine, a local anaesthetic with anti-inflammatory and antibacterial properties, designed for the treatment of oral mucositis in cancer patients. CAM2028 aims to provide an extended analgesic effect as well as protection for damaged mucosal surfaces. The product is based on the proprietary FluidCrystal® drug delivery system and is administered as a lipid-based solution that spreads across damaged mucosal surfaces. Directly after administration, CAM2028 forms a mucoprotective and drug encapsulating liquid crystal gel, providing extended release of benzydamine.

In a recent Phase I/II trial, four different oromucosal benzydamine formulations were evaluated for safety, tolerability, spatial distribution and duration in patients with oral mucositis. The best candidate formulation, which successfully met the objectives of the study, was selected for further clinical assessment in the current Phase II trial.

The trial will be conducted in five centres and is expected to enrol 50 patients by the third quarter of 2007. Head-and-neck cancer patients suffering from radiation-induced oral mucositis will receive CAM2028 and placebo in a crossover trial design. The main objective of the study is to demonstrate the extended local analgesic effect of the benzydamine FluidCrystal® product. Endpoints for the trial include pain control, effect on the ability to swallow and oral mucositis status, as well as assessment of safety and tolerability.

CAMURUS AB is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical and biotech companies worldwide, the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products and to revive stalled pipeline projects.

For further information, please contact:
Fredrik Tiberg, President & CEO, Head of R&D, +46 (0)46 286 3863, info@camurus.com


2006-04-06
Per-Anders Abrahamsson new board member of Camurus AB

Professor Per-Anders Abrahamsson, MD, PhD, has been elected as new member of Camurus’ Board of Directors. Dr. Abrahamsson is an international opinion leader in urology.

Dr. Abrahamsson is Professor of Urology at Lund University, Chairman of the Department of Urology at Malmö University Hospital, Sweden, and Adjunct Professor at the Department of Urology, University of Rochester Medical Center, Rochester, New York, USA.  Since 2004 he is Adjunct Secretary-General in the European Association of Urology, and is in charge of the organization’s research activities. He has previously also served as Chairman of Department of Urology, Lund University Hospital, Lund, Sweden.

Dr. Abrahamsson received his MD and PhD from Lund University and has participated in a large number of clinical trials. He is author of 275 scientific publications including book chapters and books, and member of the Editorial Boards of several scientific journals. Dr. Abrahamsson has been main organizer of international conferences, is a frequently invited speaker at scientific meetings, and has received a number of national and international awards.

With his academic stature and deep understanding of both basic and clinical research Per-Anders Abrahamsson will contribute crucial experience to Camurus at a time when our research and development pipeline is expanding strongly” says CEO Fredrik Tiberg.  “It is great pleasure for us to bring in Per-Anders as a new board member.”

CAMURUS is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical manufacturers the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products, and to revive stalled pipeline projects.

For further information, please contact:
Fredrik Tiberg, President & CEO, Head of R&D, +46 (0) 46 286 3863, info@camurus.ideon.se


2006-03-20
Camurus starts phase I clinical trial with CAM2029 – a new long-acting octreotide depot

The Swedish Medical Products Agency has approved Camurus’ Clinical Trial Application (CTA) for Phase I trials of CAM2029, the company's product candidate for the treatment of acromegaly and carcinoid tumours. The study starts in April 2006.

Acromegaly is a rare chronic and insidious hormonal disorder that occurs when the pituitary gland produces excess growth hormone (GH) leading to the subsequent elevation of insulin-like growth factor-1 levels (IGF-1). It most commonly affects middle-aged adults and may lead to premature death. Symptoms of this condition include abnormal skeletal growth deformities (particularly of the hands, feet, and face) cardiovascular disease, neuropathy, respiratory disease, and malignancy.

Carcinoid tumour is an intestinal tumour which arises from specialised cells with paracrine functions. The primary tumour is commonly in the appendix, where it is clinically benign. Secondary, metastatic, intestinal carcinoid tumours secrete excessive amounts of vasoactive substances and polypeptide hormones. These tumours may grow anywhere in the gastrointestinal tract, and in the lungs, with approximately 90% in the appendix. The clinical condition is Carcinoid Syndrome which is manifested by symptoms of episodic cutaneous flushing, abdominal cramps and diarrhoea, heart valvular lesions, peripheral edema, wheezing, cyanosis, and arthritis.

The new product, denoted CAM2029, is a long-acting injectable depot of octreotide acetate based on Camurus’ in-situ forming, liquid crystal (LC) gel technology, which facilitates time-release injectable depots that slowly deliver drugs to plasma to improve compliance and create a more therapeutic profile. Octreotide is a synthetic analogue of somatostatin, a naturally occurring hormone peptide that signals to the pituitary to reduce growth hormone production. In clinical practice the compound is used to treat acromegaly and the carcinoid syndrome by controlling hormonal hypersecretion.

CAM2029 is a sustained release formulation of octreotide designed to give a fast and controlled onset of action without the need for supplementary daily dosing during initial depot treatment. The product will be provided in ready-to-use form thus also facilitating ease of handling and administration.

The clinical study, which will enrol 32 healthy volunteers, has been designed for assessment of tolerability, pharmacokinetics, and pharmacodynamics. This is a double-blind, randomised, placebo-controlled, single dose study of three different dose volumes of octreotide, given by subcutaneous injection, and one dose volume by intramuscular injection.

CAMURUS is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical manufacturers the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products, and to revive stalled pipeline projects.

For further information, please contact:
Fredrik Tiberg, President & CEO, Head of R&D, +46 (0)46 286 3863, info@camurus.com


2005-10-05
Camurus initiates clinical trial of new product candidate in patients with oral mucositis

Camurus has initiated a Phase I/IIa clinical study to evaluate safety, tolerability and preliminary efficacy of CAM2028; an oromucosal formulation of an agent being used for topical treatment of pain in cancer patients with oral mucositis (OM).

Mucositis is an inflammation and ulceration of the lining of the mouth, throat or gastrointestinal tract most commonly associated with chemotherapy or radiotherapy for cancer. OM is the most commonly experienced manifestation occurring in around 40% of cancer patients. It is a severe side effect that can limit the patient’s ability to tolerate cancer therapy. In more severe cases, mucositis can be extremely painful, preventing the patient from eating and necessitating hospitalisation for re-hydration, narcotic pain medication, and/or total parenteral nutrition. The destruction of the protective mucous membrane can also place the patient at a serious risk of infection. OM is an indication with high unmet medical needs.

There are presently several analgesic treatments available. However, the duration of the analgesic effect of these products is short and the efficacy limited. CAM2028 is intended to combine rapid onset and prolonged pain relief locally in the oral cavity.

The clinical study of CAM2028 was started in September 2005 and is conducted in cancer patients with radiotherapy induced OM. The aims are to evaluate safety, tolerability and duration of different oromucosal drug candidate products. In addition, comparison of patient’s subjective acceptability as well as preliminary evaluation of the analgesic effects is performed. The study will be completed before the end of the year.

CAMURUS AB is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical manufacturers the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products, and to revive stalled pipeline projects.

For further information, please contact:
Fredrik Tiberg, President & CEO, Head of R&D, +46 (0)46 286 3863, info@camurus.ideon.se


2005-08-25
Camurus reports new innovation in nanotechnology: High-definition lipid superstructures

Scientists at Camurus report preparation of novel lipid nanoparticles; featured on the cover of the August 2005 issue of Nano Letters.

The new findings, published in the Nano Letters, Vol. 5, 2005, pp 1615-1619, describe self-assembled liquid crystal nanoparticles with improved characteristics over current liposome and vesicle structures, including key properties like loading capacity, stability, size distribution, reproducibility, and scalability.  “These advances are important for commercial applications in many areas - from biomimetics and in vivo delivery carriers, both for therapeutic and diagnostic agents, to protein crystallization and new nanoporous materials.” says Fredrik Tiberg, President & CEO of Camurus. “CAMURUS is well-positioned and committed to continue leading innovation in nanotechnology.”

CAMURUS AB is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical manufacturers the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products, and to revive stalled pipeline projects.

For further information, please contact:
Fredrik Tiberg, President & CEO, Head of R&D, +46 (0)46 286 3863,
info@camurus.ideon.se


2005-05-27
New generation of injectable depot system for peptide and protein therapeutics

Camurus has successfully completed pre-clinical evaluations, including safety studies, of its new generation long-acting injectable depot designed for delivery of peptide and protein drug products.

In pre-clinical Proof-of-Concept studies the company's in situ forming liquid crystal (LC) depot was found to continuously deliver therapeutic levels of a peptide during a six-week period. Compare to competing micro-particle technologies, Camurus' proprietary system has several advantageous features including tuneable pharmacokinetics, more stable plasma levels, rapid onset, easier manufacturing, and convenient administration.

With this development, the Scandinavian-based biotechnology company Camurus continues to build its array of advanced drug delivery systems (DDS) for biopharmaceuticals as well as small molecule drugs. Following the successful pre-clinical safety and pharmacokinetic evaluations, the new depot system is currently being assessed in multiple drug development projects, both in-house and with partners. The first clinical study will be started in December 2005.

“Camurus has taken another important step towards becoming the leading provider of advanced, lipid-based drug delivery systems. We are in an expansive and creative phase with a number of ongoing drug development projects in different stages of development and 2005 is definitely the break-through year. The creativity is reflected by over 20 patent priotrity applications submitted by the company scientists during the past 18 months. Several potential drug candidates are also under assessment together with our partners. The introduction of two new drug delivery systems, launch of three clinical development programs, and execution of several Feasibility Programs with strategic pharmaceutical and biotech partners is promising for the future," says Fredrik Tiberg, President & CEO of Camurus.  To facilitate the anticipated expansion of operations the company has invested in new laboratories, including a new facilities for pre-clinical testing, and increased the office space at the head-quarter in Lund

CAMURUS AB is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical manufacturers the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products, and to revive stalled pipeline projects.

For further information, please contact:
Fredrik Tiberg, President & CEO, Head of R&D, +46 (0)46 286 3863,
info@camurus.ideon.se


2005-03-15
Research grant for development of pulmonary drug delivery system

Camurus receives a second grant from Swedish Agency for Innovation Systems, VINNOVA, to develop a novel proprietary low-density particle technology for pulmonary delivery of drug substances.

As with all Camurus' drug delivery platforms this technology is based on a truly innovative approach of producing functional lipid nanostructures by lipid self-assembly processes. While the Company has documented drug delivery systems (DDS) for oral, parenteral and topical administration already on the market or in late pre-clinical and clinical studies, the pulmonary technology is still in an early development stage. "VINNOVA's support of strategic technology and product developments is important to Camurus' ambitious goal to offer a broad portfolio of advanced and effective drug delivery solutions accross different administration routes", says Fredrik Tiberg, President & CEO of Camurus.

The project Particles for Inhalation with a total budget of 2.1 M SEK is Camurus' second strategic research project to receive funding from Swedish Agency for Innovation Systems VINNOVA. The first program New Strategies for Oral Delivery of Drug Peptides and Peptidomimetics approaches its third year with a total budget of more than 6 M SEK. This is a collaborative program with Lund University; currenty involving ten doctoral, post-doctoral and senior scientists. "These projects enable us to perform strategic research activities of critical importance to the development of our future generations of innovative drug delivery systems – and ultimately to develop better non-invasive therapeutic products for treatment of serious medical conditions" says Fredrik Tiberg.

CAMURUS AB is a leading provider of drug delivery systems for peptides, proteins, and insoluble drugs. Working closely with pharmaceutical manufacturers the company's proprietary technologies make it possible to introduce new therapeutic products, improve the efficacy of existing products, and to revive stalled pipeline projects.

For further information, please contact
Fredrik Tiberg, President & CEO, Head of R&D, +46 (0)46 286 3863,


NEWS
 
Go to newsarchive »



© CAMURUS AB • Ideon Science Park, SE-223 70 Lund, Sweden • Phone: +46 46 286 57 30 • E-mail: info@camurus.com
www.camurus.com